Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

History of the prevention of mother-to-child transmission of HIV in Thailand.

Phanuphak N, Phanuphak P.

J Virus Erad. 2016 Apr 1;2(2):107-9.

2.

Simplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide Ligation.

Panpradist N, Beck IA, Chung MH, Kiarie JN, Frenkel LM, Lutz BR.

PLoS One. 2016 Jan 11;11(1):e0145962. doi: 10.1371/journal.pone.0145962. eCollection 2016.

3.

Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.

Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators.

AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.

4.

Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.

Antunes F, Zindoga P, Gomes P, Augusto O, Mahumane I, Veloso L, Valadas E, Camacho R.

PLoS One. 2015 Jul 10;10(7):e0131994. doi: 10.1371/journal.pone.0131994. eCollection 2015.

5.

Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa.

Mensch BS, Gorbach PM, Kelly C, Kiepiela P, Gomez K, Ramjee G, Ganesh S, Morar N, Soto-Torres L, Parikh UM.

AIDS Behav. 2015 Nov;19(11):2076-86. doi: 10.1007/s10461-015-1056-4.

6.

The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.

Wang Y, Xing H, Liao L, Wang Z, Su B, Zhao Q, Feng Y, Ma P, Liu J, Wu J, Ruan Y, Shao Y.

AIDS Res Ther. 2014 Nov 21;11:36. doi: 10.1186/1742-6405-11-36. eCollection 2014.

7.

Fibrinolytic changes in pregnant women on highly active antiretroviral therapy.

Osime OE, Ese-Onakewhor JU, Kolade SO.

Saudi Med J. 2015 Feb;36(2):200-3. doi: 10.15537/smj.2015.2.10372.

8.

Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.

Vogler MA, Smeaton LM, Wright RL, Cardoso SW, Sanchez J, Infante R, Moran LE, Godfrey C, Demeter LM, Johnson VA.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):542-50. doi: 10.1097/QAI.0000000000000072.

9.

Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment.

Grijsen ML, Wit FW, Jurriaans S, Kroon FP, Schippers EF, Koopmans P, Gras L, Lange JM, Prins JM; Primo-SHM Study Group.

PLoS One. 2014 Apr 3;9(4):e89639. doi: 10.1371/journal.pone.0089639. eCollection 2014.

10.

Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.

Nishizawa M, Hattori J, Shiino T, Matano T, Heneine W, Johnson JA, Sugiura W.

PLoS One. 2013 Dec 16;8(12):e83150. doi: 10.1371/journal.pone.0083150. eCollection 2013.

11.

Representation of women and pregnant women in HIV research: a limited systematic review.

Westreich D, Rosenberg M, Schwartz S, Swamy G.

PLoS One. 2013 Aug 23;8(8):e73398. doi: 10.1371/journal.pone.0073398. eCollection 2013. Review.

12.

Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.

Permar SR, Salazar MG, Gao F, Cai F, Learn GH, Kalilani L, Hahn BH, Shaw GM, Salazar-Gonzalez JF.

Retrovirology. 2013 Aug 14;10:88. doi: 10.1186/1742-4690-10-88.

13.

Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention.

Gupta RK, Van de Vijver DA, Manicklal S, Wainberg MA.

Retrovirology. 2013 Jul 31;10:82. doi: 10.1186/1742-4690-10-82. Review.

14.

Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy.

Westreich D, Maskew M, Evans D, Firnhaber C, Majuba P, Sanne I.

PLoS One. 2013;8(3):e58117. doi: 10.1371/journal.pone.0058117. Epub 2013 Mar 8.

15.

Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.

Micek MA, Blanco AJ, Carlsson J, Beck IA, Dross S, Matunha L, Seidel K, Montoya P, Gantt S, Matediana E, Jamisse L, Gloyd S, Frenkel LM.

J Infect Dis. 2012 Jun 15;205(12):1811-5. doi: 10.1093/infdis/jis282. Epub 2012 Apr 5.

16.

Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.

Lehman DA, Wamalwa DC, McCoy CO, Matsen FA, Langat A, Chohan BH, Benki-Nugent S, Custers-Allen R, Bushman FD, John-Stewart GC, Overbaugh J.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):225-33. doi: 10.1097/QAI.0b013e3182515730.

17.

Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.

Hauser A, Sewangi J, Mbezi P, Dugange F, Lau I, Ziske J, Theuring S, Kuecherer C, Harms G, Kunz A.

PLoS One. 2012;7(2):e32055. doi: 10.1371/journal.pone.0032055. Epub 2012 Feb 23.

18.

Applications of next-generation sequencing technologies to diagnostic virology.

Barzon L, Lavezzo E, Militello V, Toppo S, Pal├╣ G.

Int J Mol Sci. 2011;12(11):7861-84. doi: 10.3390/ijms12117861. Epub 2011 Nov 14. Review.

19.

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.

Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, Frenkel L, Britto P, Roongpisuthipong A, Beck IA, Yuthavisuthi P, Prommas S, Puthanakit T, Achalapong J, Chotivanich N, Rasri W, Cressey TR, Maupin R, Mirochnick M, Jourdain G; IMPAACT P1032 Protocol Team.

Clin Infect Dis. 2012 Jan 15;54(2):285-93. doi: 10.1093/cid/cir798. Epub 2011 Dec 5.

20.

Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

Zorrilla CD, Tamayo-Agrait V.

HIV AIDS (Auckl). 2009;1:41-53. Epub 2009 Dec 8.

Supplemental Content

Support Center